Human LYPD3 Protein (LPD-HM103)

  • Express System: Expi293
  • Product Tag: C-His
  • Purity: > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
  • Activity: Immobilized Human LYPD3, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LYPD3 Ab., hFc Tag with the EC50 of 11.6ng/ml determined by ELISA. See testing image for detail.
  • Exact Sequence: Leu31-His286

Catalog: LPD-HM103

$263.00
Size:

Order now get it on

Product Description Recombinant Human LYPD3 Protein is expressed from Expi293 with His tag at the C-terminal.; It contains Leu31-His286.
Product Category Recombinant Protein
Target LYPD3
Synonyms MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3
Gene/Protein ID O95274
Species Human
Exact Sequence Leu31-His286
Molecular Weight The protein has a predicted MW of 27.8 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
Activity Immobilized Human LYPD3, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LYPD3 Ab., hFc Tag with the EC50 of 11.6ng/ml determined by ELISA. See testing image for detail.
Product Tag C-His
Express System Expi293
Purity > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin Less than 1EU per μg by the LAL method.
Form Liquid
Shipping Shipped with blue ice or dry ice.
Formulation Supplied as 0.22μm filtered solution in PBS (pH 7.4). Please dilute to the desired concentration according to the concentration of the solution shown on the product label.
Stability And Storage Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Immobilized Human LYPD3, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LYPD3 Ab., hFc Tag with the EC50 of 11.6ng/ml determined by ELISA.
The purity of Human LYPD3 is greater than 95% as determined by SEC-HPLC.
Human LYPD3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

You may also be interested in